Logo

Circulogene Microsatellite Instability Biomarker Testing

Nov 15, 2017

Circulogene announced the availability of microsatellite instability biomarker testing for multiple cancer types. The test is immediately available to oncologists and pathologists, enabling them to identify patients eligible for treatment with Keytruda (pembrolizumab) across multiple cancer types, or Opdivo (nivolumab) for colorectal cancer. With the new assay, Circulogene now provides circulating DNA, RNA, and MSI cancer immunotherapy testing from a single tube of blood with a three-day turnaround time out of it CLIA-certified laboratory.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.